OraSure rated at sector perform by RBC

RBC Capital Markets analyst William R. Quirk rated OraSure Technologies, Inc. at sector perform, speculative risk, and an $11 price target. The company's rapid hepatitis C virus test showed 99.6% sensitivity and 99.6% specificity in preliminary studies. RBC expects a rapid HCV test to add to revenue starting in mid-2008 and forecasts a 2007 revenue estimate of $97.8 million. Shares of the Bethlehem, Pa.-based pharmaceutical company were up 16 cents, or 2.00%, at $8.18 on volume of 487,629 shares versus the three-month running average of 493,343 shares. (Nasdaq: OSUR)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.